Skip to main content
. 2019 Apr 9;8(5):2064–2073. doi: 10.1002/cam4.2091

Figure 2.

Figure 2

CR (no emesis, no rescue medication) rates in the delayed phase (>24‐120 h) of cycles 1‐4 in: A) Study 1 (patients receiving AC‐based chemotherapy), and B) Study 2 (patients receiving HEC or MECa). Full analysis set. aBreast cancer patients were not allowed AC‐based regimens. AC, anthracycline‐cyclophosphamide; APR, aprepitant; CR, complete response; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; NEPA, netupitant‐palonosetron; PALO, palonosetron